Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPFZ.L Regulatory News (PFZ)

  • There is currently no data for PFZ

Rule 38.5 - Replacement Pfizer INC

4 Nov 2015 17:37

RNS Number : 6121E
Morgan Stanley Capital Services LLC
04 November 2015
Β 

ο»Ώ

AMENDMENT (Section 2 b)

Β FORM 38.5(a)

Β 

IRISHΒ TAKEOVERΒ PANEL

Β 

DISCLOSUREΒ UNDERΒ RULEΒ 38.5(a)Β OFΒ THEΒ IRISHΒ TAKEOVERΒ PANELΒ ACT,Β 1997, TAKEOVER Β RULES,Β 2013

Β 

DEALINGS BY CONNECTEDΒ EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARYΒ STATUS AND DEALING IN A CLIENT-SERVING CAPACITY

Β 

Β 

1. KEYΒ INFORMATION

Β Name of exempt market-maker

Morgan Stanley Capital Services LLC

Β Company dealt in

PFIZER INC

Β Class of relevant security to which the dealings being disclosed relate (Note 1)

US$0.05 common stock

Β Date of dealing

30 OCTOBER 2015

Β 

Β 

2. DEALINGSΒ (NoteΒ 2)

Β 

(a) PurchasesΒ andΒ sales

Β Total number of relevant securities acquired

Β Highest price paid (Note 3)

Β Lowest price paid (Note 3)

Β Β 312,656

Β 34.8300 USD

Β 33.7779 USD

Β 

Β Total number of relevant securities disposed

Β Highest price paid (Note 3)

Β Lowest price paid (Note 3)

Β Β 237,803

Β 34.8900 USD

Β 33.7400 USD

Β 

Β 

(b) DerivativesΒ transactionsΒ (otherΒ thanΒ optionsΒ transactions)

Β 

Β Product name, e.g. CFD

Β Nature of transaction

(Note 4)

Β Number of relevant securities

(Note 5)

Β Price per unit

Β CFD

Β LONG

Β 1,400

Β 33.8200 USD

Β CFD

Β LONG

Β 2,941

Β 33.8200 USD

Β CFD

Β LONG

Β 1,840

Β 33.9411 USD

Β CFD

Β LONG

Β 25,200

Β 33.9437 USD

Β CFD

Β LONG

Β 2,000

Β 33.9550 USD

Β CFD

Β LONG

Β 1,704

Β 33.9637 USD

Β CFD

Β LONG

Β 14,687

Β 33.9637 USD

Β CFD

Β LONG

Β 7,577

Β 33.9637 USD

Β CFD

Β LONG

Β 11

Β 33.9798 USD

Β CFD

Β LONG

Β 32

Β 33.9798 USD

Β CFD

Β LONG

Β 1

Β 33.9798 USD

Β CFD

Β LONG

Β 150

Β 33.9798 USD

Β CFD

Β LONG

Β 222

Β 33.9827 USD

Β CFD

Β LONG

Β 20

Β 33.9827 USD

Β CFD

Β LONG

Β 61

Β 34.0000 USD

Β CFD

Β LONG

Β 28,483

Β 34.0977 USD

Β CFD

Β LONG

Β 1,200

Β 34.2800 USD

Β CFD

Β LONG

Β 3

Β 34.4212 USD

Β CFD

Β LONG

Β 5

Β 34.4212 USD

Β CFD

Β LONG

Β 800

Β 34.4788 USD

Β CFD

Β SHORT

Β 114

Β 33.8096 USD

Β CFD

Β SHORT

Β 57,493

Β 33.9431 USD

Β CFD

Β SHORT

Β 1,000

Β 33.9500 USD

Β CFD

Β SHORT

Β 4,200

Β 33.9522 USD

Β CFD

Β SHORT

Β 4,200

Β 33.9557 USD

Β CFD

Β SHORT

Β 2,200

Β 33.9582 USD

Β CFD

Β SHORT

Β 200

Β 33.9800 USD

Β CFD

Β SHORT

Β 10

Β 33.9900 USD

Β CFD

Β SHORT

Β 38

Β 33.9900 USD

Β CFD

Β SHORT

Β 15

Β 33.9900 USD

Β CFD

Β SHORT

Β 4

Β 33.9900 USD

Β CFD

Β SHORT

Β 141

Β 34.0129 USD

Β CFD

Β SHORT

Β 88

Β 34.0129 USD

Β CFD

Β SHORT

Β 600

Β 34.0633 USD

Β CFD

Β SHORT

Β 1,300

Β 34.0763 USD

Β CFD

Β SHORT

Β 3,094

Β 34.1462 USD

Β CFD

Β SHORT

Β 212

Β 34.1462 USD

Β CFD

Β SHORT

Β 15

Β 34.1462 USD

Β CFD

Β SHORT

Β 26

Β 34.1462 USD

Β CFD

Β SHORT

Β 670

Β 34.1462 USD

Β CFD

Β SHORT

Β 364

Β 34.1722 USD

Β CFD

Β SHORT

Β 933

Β 34.1722 USD

Β CFD

Β SHORT

Β 1,889

Β 34.2254 USD

Β CFD

Β SHORT

Β 112,716

Β 34.4194 USD

Β 

Β 

(c) OptionsΒ transactionsΒ inΒ respectΒ ofΒ existingΒ relevantΒ securities

Β 

i) Writing,Β selling,Β purchasingΒ orΒ varying

Β 

Β Product name, eg call option

Β Writing, selling, purchasing, varying etc

Β Number of securities to which the option relates (Note 5)

Β Exercise Price

Β Type, e.g American, European etc

Β Expiry Date

Β Option money paid/received per unit (Note 3)

Β N/A

Β N/A

Β N/A

Β N/A

Β N/A

Β N/A

Β N/A

Β 

(ii) Exercising

Β 

Β Product name, eg call option

Β Number of securities

Β Exercise price per unit (Note 3)

Β N/A

Β N/A

Β N/A

Β 

Β 

3. OTHER INFORMATION

Β 

Agreements, arrangements or understandings relating to options or derivatives

Β 

Full Details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β Date of disclosure

Β 04 NOVEMBER 2015

Β Contact Name

Craig Horsley

Β Telephone Number

+44(141) 245 7736

Β Name of offeree/offeror with which connected

ALLERGAN PLC

Nature of connection (Note 6)

Advisory

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
ISEPKQDNOBDDQDK
Date   Source Headline
8th May 201411:35 amBUSForm 8.3 - Pfizer Inc
8th May 201411:21 amRNSForm 8.3 - [Pfizer Inc]
8th May 201411:20 amRNSForm 8.3 - [AstraZeneca Plc]
8th May 201411:14 amRNSForm 8.3 - Pfizer Inc
8th May 201411:02 amRNSRule 2.10 Announcement
8th May 201410:46 amRNSForm 8.5 (EPT/RI) Replacement - Pfizer INC
8th May 201410:45 amRNSForm 8.5 (EPT/RI)Replacement - Pfizer INC
8th May 201410:45 amRNSForm 8.5 (EPT/RI) Replacement - Pfizer INC
8th May 201410:15 amRNSForm 8.5 (EPT/RI)Replacement - Pfizer INC
8th May 201410:13 amRNSForm 8.5 (EPT/RI)Replacement Pfizer INC
8th May 201410:08 amRNSForm 8.5 (EPT/RI) Astrazeneca PLC
8th May 201410:07 amRNSForm 8.5 (EPT/RI) Astrazeneca PLC
8th May 201410:06 amRNSForm 8.5 (EPT/RI) Pfizer Inc
8th May 201410:05 amRNSForm 8.5 (EPT/RI)Pfizer INC
8th May 20149:53 amRNSRule 2.10 Announcement
8th May 20147:00 amRNSForm 8 (DD) - Pfizer Inc.
8th May 20147:00 amRNSForm 8 (DD) - Pfizer Inc. - Amendment
8th May 20147:00 amPRNForm 8.3 - Pfizer Inc.
7th May 20145:34 pmBUSForm 8.3 - Pfizer Inc
7th May 20145:24 pmRNSForm 8.5 (EPT/RI) - Amendment
7th May 20145:20 pmRNSForm 8.3 - [Pfizer/Astrazeneca] Amendment s.2
7th May 20145:19 pmRNSForm 8.3 - [Pfizer/Astrazeneca] Amendment s.2
7th May 20145:15 pmRNSForm 8.3 - [Pfizer/Astrazeneca] Amendment s.2
7th May 20145:07 pmRNSForm 8 (DD) - [Pfizer Inc] - Amendment
7th May 20144:56 pmBUSForm 8.3 - Pfizer Inc
7th May 20144:55 pmRNSForm 8.5 (EPT/RI) - Amendment
7th May 20143:45 pmRNSForm 8.3 - PFIZER INC
7th May 20143:33 pmRNSForm 8.3 - Pfizer Inc
7th May 20143:27 pmRNSForm 8.3 - Pfizer Inc Amendment
7th May 20143:25 pmBUSForm 8.3 - Pfizer Inc.
7th May 20143:24 pmRNSForm 8.3 - AstraZeneca Plc
7th May 20143:23 pmRNSForm 8.3 - Pfizer Inc
7th May 20143:17 pmRNSForm 8.3 - [Pfizer Inc]
7th May 20143:00 pmRNSForm 8.3 - AstraZeneca PLC
7th May 20142:41 pmRNSForm 8 (DD) - Pfizer Inc. - Amendment
7th May 20142:30 pmBUSForm 8.3 - Pfizer Inc - AMENDMENT
7th May 20142:23 pmRNSForm 8.3 - Pfizer Inc
7th May 20142:19 pmBUSForm 8.3 - Pfizer Inc.
7th May 20141:42 pmBUSForm 8.3 - Pfizer Inc.
7th May 20141:41 pmBUSForm 8.3 - Pfizer Inc
7th May 20141:38 pmRNSForm 8.3 - Pfizer Inc
7th May 20141:23 pmRNSForm 8.3 - AstraZeneca Plc
7th May 201412:32 pmRNSForm 8.5 (EPT/NON-RI)
7th May 201412:29 pmRNSForm 8.3 - Pfizer Inc
7th May 201412:23 pmRNSForm 8.5 (EPT/RI)
7th May 201411:55 amRNSForm 8.3 - Pfizer, Inc.
7th May 201411:42 amRNSForm 8 (DD) - [Pfizer Inc]
7th May 201411:38 amRNSForm 8 (DD) - [Pfizer Inc]
7th May 201411:33 amRNSForm 8.5 (EPT/RI)
7th May 201411:27 amRNSForm 8.3 - Pfizer Inc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.